Hurdles in therapy with regulatory T cells

Piotr Trzonkowski, Rosa Bacchetta, Manuela Battaglia, David Berglund, Hermann Richard Bohnenkamp, Anja ten Brinke, Andrew Bushell, Nathalie Cools, Edward K Geissler, Silvia Gregori, S Marieke van Ham, Catharien Hilkens, James A Hutchinson, Giovanna Lombardi, J Alejandro Madrigal, Natalia Marek-Trzonkowska, Eva M Martinez-Caceres, Maria Grazia Roncarolo, Silvia Sanchez-Ramon, Aurore SaudemontBirgit Sawitzki

    Research output: Contribution to journalArticlepeer-review

    127 Citations (Scopus)


    Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.

    Original languageEnglish
    Pages (from-to)304ps18
    JournalScience Translational Medicine
    Issue number304
    Publication statusPublished - 9 Sept 2015


    • Clinical Trials as Topic
    • Drug Approval
    • Humans
    • Immunotherapy
    • T-Lymphocytes, Regulatory
    • Treatment Outcome


    Dive into the research topics of 'Hurdles in therapy with regulatory T cells'. Together they form a unique fingerprint.

    Cite this